Published in final edited form as:

Biochem Biophys Res Commun. 2012 May 4; 421(2): 177–183. doi:10.1016/j.bbrc.2012.03.128.

LIPID RAFTS AND FUNCTIONAL CAVEOLAE REGULATE HIV-INDUCED AMYLOID BETA ACCUMULATION IN BRAIN ENDOTHELIAL CELLS

Ibolya E. András, Sung Yong Eum, and Michal Toborek

Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, FL

Ibolya E. András: IAndras@med.miami.edu; Sung Yong Eum: SEum@med.miami.edu; Michal Toborek: MToborek@med.miami.edu

Abstract

Amyloid beta ($A\beta$) levels are increased in HIV-1 infected brains due to not yet fully understood mechanisms. In the present study, we investigate the role of lipid rafts, functional caveolae, and caveolae-associated signaling in HIV-1-induced $A\beta$ accumulation in HBMEC. Both silencing of caveolin-1 (cav-1) and disruption of lipid rafts by pretreatment with beta-methyl-cyclodextrin (MCD) protected against $A\beta$ accumulation in HBMEC. Exposure to HIV-1 and $A\beta$ activated caveolae-associated Ras and p38. While inhibition of Ras by farnesylthiosalicylic acid (FTS) effectively protected against HIV-1-induced accumulation of $A\beta$, blocking of p38 did not have such an effect. We also evaluated the role of caveolae in HIV-1-induced upregulation of the receptor for advanced glycation end products (RAGE), which regulates $A\beta$ transfer from the blood stream into the central nervous system. HIV-1-induced RAGE expression was prevented by infecting HBMEC with cav-1 specific shRNA lentiviral particles or by pretreatment of cells with FTS. Overall, the present results indicate that $A\beta$ accumulation in HBMEC is lipid raft and caveolae dependent and involves the caveolae-associated Ras signaling.

Keywords

HIV-1; blood-brain barrier; amyloid beta

INTRODUCTION

Due to the success of antiretroviral therapy (ART), which changed the clinical picture of HIV-1 infection from acute to chronic disorder, there is a sharp increase in infected patients 50 years old and older [1]. In addition, the rate of new infections is also climbing in older people. This increase in age of the HIV-1 infected population constitutes a new challenge in the HIV/AIDS epidemic in the affluent countries. Indeed, older HIV-1 infected patients are

© 2012 Elsevier Inc. All rights reserved.

Correspondence: Michal Toborek, MD, PhD; Department of Biochemistry and Molecular Biology; University of Miami School of Medicine; 1011 NW 15th Street; Gautier Building, Room 517; Miami FL, 33136-1019, USA, phone number: (305) 243-0230; MToborek@med.miami.edu.

Conflict of interest: The authors have no conflicting interests to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

more susceptible to neurocognitive impairments associated with the disease [2], and a significantly higher prevalence of dementia was observed in aged HIV-1-infected individuals as compared to younger patients [3]. Increased deposition of amyloid beta is also a characteristic in the HIV-1 infected brains [2,4]. HIV-associated neurocognitive disorders (HAND) in older patients appeared to correlate with early beta-amyloidosis characteristic for the Alzheimer's disease (AD) even if amyloid pathology is different in HIV-1 and AD [1]. A β accumulation in the brain may also affect the rate of HIV-1 infection probably via activated microglia and macrophages since these cell types have been found in the proximity to amyloid plaques [5].

The aim of the present study was to evaluate the role of lipid rafts and functional caveolae in A β accumulation in brain endothelial cells. This focus was prompted by the following factors: a) the receptor for advanced glycation end products (RAGE), which may be involved in A β uptake by endothelial cells, is localized to caveolae [6,7]; b) caveolin-1 was shown to play a role in activation of RAGE [8]; and c) HIV-1 Tat can activate the caveolae-associated pathway in brain endothelial cells [9].

MATERIALS AND METHODS

Cell culture and treatment

Human brain microvascular endothelial cells (HBMEC) and human monocytic U937 cells were co-cultured as described earlier [10]. Cells were treated with freshly solubilized A β (1–40) (Anaspec, San Jose, CA) at the concentration of 1 μ M for 10 min in complete medium.

HIV-1 stock was generated using human embryonic kidney (HEK) 293T cells (American Type Culture Collection, Manassas, VA) and used to infect U937 cells [10]. In the co-culture experiments, confluent HBMEC cultures growing on 6-well plates were exposed to U937 cells at a ratio of 1:1 and HIV-1 p24 at a level of 230 pg/ml. Non-infected U937 cells were used as controls. In the monoculture experiments confluent HBMEC cultured on collagen I coated chambered glass slides (BD Biosciences, San Jose, CA) were exposed to HIV-1 particles (initial p24 level of 30 ng/ml; final p24 level of 1 ng/ml).

Caveolin-1 silencing and shRNA lentiviral particles infection

Caveolin-1 (cav-1) silencing was performed as described by Lim et al (2008) using a mixture of siRNA corresponding to the nucleotides 69–87 of the human cav-1 mRNA sequence: 5'-CAUCUACAAGCCCAACAA C-dTdT-3' (cav-1 siRNA-1) and to the nucleotides 223–241: 5'-CCAGAAGGGACACACAGUU-dTdT-3' (cav-1 siRNA-2). Control siRNA was: 5'-AAAGAGCGACUUUACACAC-dTdT-3'.

HBMEC were infected with shRNA lentiviral particles containing target-specific constructs that encode shRNA designed to knock down cav-1 expression (Santa Cruz Biotechnology) using the manufacturer's instructions.

Purification of lipid rafts

Lipid raft membranes were prepared as described by Lim et al [11] with minor modifications. Briefly, cells were solubilized in 1 ml of ice-cold MNE buffer (25 mM MES [morpholineethanesulfonic acid, pH 6.5]; 150 mM NaCl; 5 mM EDTA) with 1 mM sodium orthovanadate, protease inhibitors and 1% Triton X-100 on ice. The cell lysate was then homogenized, centrifuged at 15000 $\times$ g for 15 min at 4°C, followed by sucrose gradient ultracentrifugation. Aliquots were subjected to SDS-PAGE and immunoblotting to assess flotillin-1 and cav-1 as marker proteins for lipid rafts and caveolae, respectively.

Immunoblotting and confocal immunofluorescence microscopy

Homogenates of cultured HBMEC were prepared in lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 0.1 mg/ml phenylmethylsulfonyl fluoride, 0.5% Nonidet P40, 1 mM EDTA, 2.5 µg/ml leupeptin, 1 µg/ml pepstatin A, and 1 µg/ml aprotinin) and analyzed using a standard approach. Immunofluorescence was performed and evaluated as described earlier [10].

Ras and p38 activation assays

Ras Activation ELISA Kit (Millipore, Temecula, CA) was used to assess GTP-bound Ras. ELISA (Invitrogen, Camarillo, CA) was also used to quantify phosphorylation of p38 at threonine 180 and tyrosine 182 as markers of p38 activation.

Statistical Analysis

Data were analyzed using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA). One way ANOVA was used to compare responses among treatments. Treatment means were compared using All Pairwise Multiple Comparison Procedures (Tukey Test) and $p < 0.05$ was considered significant.

RESULTS

Exposure to HIV and/or A β alters cellular distribution of lipid rafts and caveolae

The cells were fractionated by sucrose density ultracentrifugation, followed by determination of flotillin and cav-1 (markers of lipid rafts and caveolae, respectively) (Figure 1A). Treatment with A β (1 µM) for 10 min resulted in a slight shift to the heavier cellular fractions. Treatment with HIV-1 particles caused an even more visible shift to the right. Interestingly, A β co-treatment of HBMEC exposed to HIV-1 resulted in a shift to the lighter fractions. A 2 h pretreatment with farnesylthiosalicylic acid (FTS, 20 µM), a specific Ras inhibitor, followed by coexposure to A β and HIV-1 caused a flotillin-1 shift to heavier fractions.

Exposure to A β and/or HIV-1 also induced changes in cav-1 allocations to different cellular fractions (Figure 1B). Treatment with A β and HIV-1 resulted in a shift of cav-1 to heavier fractions. In cells exposed to both A β and HIV-1, the overall changes were similar to those in HIV-1-treated HBMEC; however, they were more pronounced. Interestingly, pretreatment with FTS reversed the changes in cav-1 localization in A β and HIV-1 plus A β -treated samples.

Next, we determined the localization of A β in fractionated HBMEC cells (Figure 1C). The most prominent A β immunoreactivity was detected in fractions 7 and 8; i.e., in the cellular fractions that correspond to lipid rafts and caveolae. A β immunoreactivity was increased by HIV-1 without changes in allocation of A β immunoreactivity among cellular fractions.

Disruption of lipid rafts and caveolae attenuates A β accumulation in HBMEC

Cholesterol depletion by methyl-beta-cyclodextrin (MCD; 5 mM for 30 min at 37°C) was used to disrupt lipid rafts and evaluate whether intact lipid rafts are involved in HIV-1-induced accumulation A β . While treatment with A β and, in particular, A β plus HIV-1 resulted in a significant increase in A β levels (Figure 2A), these effects were attenuated by MCD.

The protective effects of MCD on A β accumulation were confirmed in immunofluorescence microscopy studies. In these experiments, cells were exposed to A β (1–40) HiLyte Fluor 488 (producing green fluorescence) and co-stained for flotillin-1 immunoreactivity (red

fluorescence). The regions of co-localizations of A β and flotillin are marked in yellow (Figure 2B).

In order to explore the role of caveolae in A β accumulation in HBMEC, cav-1 was silenced, followed by treatment with A β (1 μ M for 10 min) and/or HIV-1 particles (p24, 1 ng/ml). As shown in Figure 2C, cav-1 silencing resulted in a marked decrease in A β levels in cells exposed to HIV-1 plus A β . To further confirm the role of cav-1 in A β accumulation, we established a cell line in which cav-1 was knocked-down by specific cav-1 shRNA. A β levels were markedly diminished in cav-1 shRNA cells treated with HIV-1 plus A β (Figure 2D), providing additional evidence that functional caveolae contribute to A β accumulation in HBMEC.

Exposure to A β or HIV-1 activates caveolae-associated Ras and p38 signaling. Ras, but not p38, is involved in HIV-1-induced A β accumulation in HBMEC

In the next series of experiments, we evaluated the effects of HIV-1 and/or A β on activation of caveolae-associated Ras and p38 signaling in HBMEC using quantitative ELISA. Treatment with A β (1 μ M) but not with HIV-1 particles (p24, 1 ng/ml) for 3 min resulted in an increase in GTP-Ras levels. However, GTP-Ras levels were increased in cells exposed to HIV-1 for 24 h. Additional exposure to A β for 3 min did not affect GTP-Ras levels as compared to cells treated with HIV-1 alone (Figure 3A).

Exposure to 1 μ M A β or HIV (p24, 1 ng/ml) for 10 min significantly increased phosphorylation of p38. In contrast, treatment with HIV for 24 h diminished levels of p-p38 as compared to control. The addition of A β had no effect on p-p38 levels in cells exposed to HIV-1 for 24 h (Figure 3B).

Pre-incubation with FTS (20 μ M; 2 h pretreatment) did not affect A β and/or HIV-1-stimulated p38 phosphorylation, indicating that activation of p38 is not dependent on Ras activation (Figure 3C). SB203580 (p38 inhibitor) served as a positive control (10 μ M; 1 h pretreatment) in these experiments.

Consistent with the results shown in Figure 2A, treatment with A β resulted in increased intracellular levels of A β and this effect was further potentiated in the presence of HIV-1 (Figure 3D). Pretreatment with FTS markedly reduced the intensity of all A β -immunoreactive bands in HIV-1 plus A β -treated cells. In cultures exposed to A β without HIV-1 co-treatment, FTS had a tendency to decrease A β levels; however, these changes did not reach statistical significance. Independent of treatment conditions, pre-exposure to SB203580 did not affect A β in HBMEC.

Functional caveolae and Ras signaling regulate HIV-1 induced RAGE overexpression

A 24 h co-culture with HIV-1-infected U937 cells increased RAGE protein levels in HBMEC transfected with control shRNA as compared to the cells co-cultured with uninfected U937 cells. This effect was blocked in cells transfected with cav-1 shRNA (Figure 4A). Pretreatment with FTS also attenuated RAGE levels in cultures exposed to HIV-1 plus A β (Figure 4B).

DISCUSSION

Lipid rafts and caveolae are important for the vascular effects of HIV. Adsorptive endocytosis by which HIV-1 can be taken up by endothelial cells involves these lipid microdomains. HIV-1 specific proteins, such as Tat and Nef, can also interact with caveolae/lipid rafts and thus exert their biological effects. Several receptors (e.g., VEGFR2 and RAGE) and signaling pathways (e.g., Ras and Rho) that are utilized by HIV-1 and HIV-1

proteins are localized to lipid rafts and caveolae in endothelial cells. Therefore, we focused on the role of these membrane domains in HIV-1-mediated alterations of A β metabolism at the BBB level.

Novel results of the present study indicate that exposure to HIV-1 viral particles can dramatically change lipid raft dynamics in HBMEC. Upon a 24 h exposure to HIV-1, lipid rafts shifted to heavier cellular fractions as assessed by determination of marker protein flotillin-1. Similar, although less dramatic, changes in lipid rafts were induced by treatment of HBMEC with A β . These findings are important because changes in lipid rafts may play a role in several brain pathologies, including neurodegenerative diseases, such as AD [12].

Specific forms of lipid rafts in vascular endothelial cells are caveolae characterized by transmembrane proteins called caveolins [13]. Cav-1 has been identified as the marker protein of caveolae, indispensable for the caveolae structure as cav-1 silencing disrupts the functional caveolae. Importantly, cav-1 was demonstrated to be up-regulated in the brains of old rats and in elderly human cerebral cortex, implying a correlation between Alzheimer's disease progression and cav-1 expression [14]. Our data indicate that treatment of HBMEC with HIV-1 and/or A β results in alterations of cellular distribution of caveolae as reflected by a shift of cav-1 to higher density cellular fractions.

The mechanisms of HIV-1 and/or A β -induced redistribution of lipid rafts and caveola are not fully understood. In cells treated with A β alone, they may involve alterations of the composition and/or solubility of these lipid domains, which are enriched in cholesterol, sphingolipids, and saturated fatty acids. Another possibility is the direct binding of A β to lipid rafts. Exposure to HIV-1 may also induce binding of the virus to lipid rafts and/or caveolae, a hypothesis that is consistent with a possible raft-dependent endocytotic entry of HIV-1 to HBMEC [15]. In support of this hypothesis, it was demonstrated that HIV-1 gp41 has a cav-1 binding domain [16].

It is important to note that A β localizes in the same cellular fractions as those with the highest detectable levels of flotillin-1 and cav-1. This correlation suggests the dependency of A β uptake and cellular accumulation on lipid rafts or caveolae. Indeed, depletion of cholesterol from cell membranes by MCD clearly demonstrated that intact lipid rafts are needed for A β uptake as MCD pretreatment drastically diminished A β accumulation in control and HIV-1 exposed HBMEC. Similar dependency of A β uptake on lipid rafts was observed in neurons [17]. In addition, disruption of caveolae by silencing of cav-1 significantly protected against A β accumulation in HBMEC.

The presence of A β in similar cell fractions as flotillin-1 and cav-1 also suggests a possible interaction of A β with lipid rafts and/or caveolae. Therefore, we also investigated the role of caveolae-associated signaling mechanisms in HIV-1-induced A β accumulation in HBMEC. We focused on the Ras-MAPK and p38-MAPK signaling pathways because Ras is involved in HIV-1-Tat induced alterations of endothelial tight junctions [18] and p38 may participate in A β uptake by neurons [19]. In addition, it was shown that p38 has an important role in the brain pathology of HIV-1 infection [for review see [20]] and its activity can be induced by A β in brain endothelial cells [21].

Consistent with earlier reports [22,23], exposure to HIV-1 or A β activated both Ras and p38. While inhibition of Ras by FTS effectively protected against HIV-1 and/or A β -induced accumulation of A β , pretreatment with the p38 inhibitor SB203580 did not affect intracellular A β levels. This finding was unexpected in the light of literature reports showing the involvement of the p38 pathway in A β pathology [24].

Among potential mechanisms that can regulate A β levels in HBMEC and its transfer across the BBB, RAGE appears to play a critical role [25]. Our previous studies demonstrated that HIV-1 exposure results in RAGE overexpression, which then contributes to increased A β accumulation in HBMEC [10]. Importantly, RAGE is present in endothelial caveolae [6] and can be activated by cav-1 [8]. In agreement with these reports, our data indicate that HIV-1-induced upregulation of RAGE protein levels can be attenuated by cav-1 depletion from HBMEC. In addition, HIV-1-induced RAGE overexpression was prevented by pretreatment with FTS, further demonstrating the dependency of RAGE on caveolae-associated pathways.

In summary, the results of the present study provide evidence that HIV-1-induced accumulation of A β in HBMEC is lipid raft and caveolae dependent. In addition, these mechanisms involve Ras signaling via upregulation of RAGE expression. Overall, these results suggest that targeting Ras signaling and/or lipid rafts may be an effective strategy to protect against HIV-1-induced A β accumulation in the brain endothelium.

Acknowledgments

pYK-JRCSF was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIH/NIAID.

This work was supported by the National Institutes of Health, grants MH63022, MH072567, DA027569, and NS39254.

Abbreviations

AD	Alzheimer's disease
Aβ	amyloid beta
ART	antiretroviral therapy
BBB	blood-brain barrier
cav-1	caveolin-1
FTS	farnesylthiosalicylic acid
HAND	HIV-associated neurocognitive disorders
HBMEC	human brain microvascular endothelial cells
HEK	human embryonic kidney cells
MCD	beta-methyl-cyclodextrin
RAGE	receptor for advanced glycation end products

References

1. Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. *J Neuroimmune Pharmacol.* 2009; 4:200–212. [PubMed: 19016329]
2. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. *J Neuroimmune Pharmacol.* 2009; 4:163–174. [PubMed: 19067177]
3. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. *Neurology.* 2004; 63:822–827. [PubMed: 15365130]

4. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. *J Neuroimmune Pharmacol.* 2009; 4:190–199. [PubMed: 19288297]
5. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature.* 2001; 410:988–994. [PubMed: 11309629]
6. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. *J Cell Biol.* 1994; 126:111–126. [PubMed: 7517942]
7. Sbai O, Devi TS, Melone MA, Feron F, Khrestchatisky M, Singh LP, Perrone L. RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. *J Cell Sci.* 2010; 123:4332–4339. [PubMed: 21098642]
8. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG, Lanting L, Natarajan R. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. *J Biol Chem.* 2006; 281:13685–13693. [PubMed: 16551628]
9. Zhong Y, Zhang B, Eum SY, Toborek M. HIV-1 Tat triggers nuclear localization of ZO-1 via Rho signaling and cAMP response element-binding protein activation. *J Neurosci.* 2012; 32:143–150. [PubMed: 22219277]
10. Andras IE, Eum SY, Huang W, Zhong Y, Hennig B, Toborek M. HIV-1-induced amyloid beta accumulation in brain endothelial cells is attenuated by simvastatin. *Mol Cell Neurosci.* 2010; 43:232–243. [PubMed: 19944163]
11. Lim EJ, Majkova Z, Xu S, Bachas L, Arzuaga X, Smart E, Tseng MT, Toborek M, Hennig B. Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells. *Chem Biol Interact.* 2008; 176:71–78. [PubMed: 18786521]
12. Yanagisawa K. GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid. *Neuroscientist.* 2005; 11:250–260. [PubMed: 15911874]
13. Simons K, Ikonen E. Functional rafts in cell membranes. *Nature.* 1997; 387:569–572. [PubMed: 9177342]
14. Kang MJ, Chung YH, Hwang CI, Murata M, Fujimoto T, Mook-Jung IH, Cha CI, Park WY. Caveolin-1 upregulation in senescent neurons alters amyloid precursor protein processing. *Exp Mol Med.* 2006; 38:126–133. [PubMed: 16672766]
15. Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. *J Virol.* 2002; 76:6689–6700. [PubMed: 12050382]
16. Benferhat R, Krust B, Rey-Cuille MA, Hovanessian AG. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. *Vaccine.* 2009; 27:3620–3630. [PubMed: 19464543]
17. Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. *J Biol Chem.* 2007; 282:35722–35732. [PubMed: 17911110]
18. Zhong Y, Smart EJ, Weksler B, Couraud PO, Hennig B, Toborek M. Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling. *J Neurosci.* 2008; 28:7788–7796. [PubMed: 18667611]
19. Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H, Sosunov A, McKhann G, Funatsu Y, Nakamichi N, Nagai T, Mizoguchi H, Ibi D, Hori O, Ogawa S, Stern DM, Yamada K, Yan SS. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. *Proc Natl Acad Sci U S A.* 2009; 106:20021–20026. [PubMed: 19901339]
20. Medders KE, Kaul M. Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. *J Neuroimmune Pharmacol.* 2011; 6:202–215. [PubMed: 21286833]
21. Hsu MJ, Hsu CY, Chen BC, Chen MC, Ou G, Lin CH. Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis. *J Neurosci.* 2007; 27:5719–5729. [PubMed: 17522316]

22. Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE. Neuroprotective activities of CEP-1347 in models of neuroAIDS. *J Immunol.* 2010; 184:746–756. [PubMed: 19966207]
23. Shen MY, Hsiao G, Fong TH, Chen HM, Chou DS, Lin CH, Sheu JR, Hsu CY. Amyloid beta peptide-activated signal pathways in human platelets. *Eur J Pharmacol.* 2008; 588:259–266. [PubMed: 18511035]
24. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. *J Neurochem.* 1999; 72:2053–2058. [PubMed: 10217284]
25. Deane R, Du Yan S, Subramanyam RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nat Med.* 2003; 9:907–913. [PubMed: 12808450]

HIGHLIGHTS

1. HIV-1 induces amyloid beta accumulation in brain endothelial cells.
2. This effect is lipid raft and caveolae dependent.
3. HIV-1 induced RAGE overexpression involves caveolae.
4. The Ras signaling pathway plays a critical a role in t HIV-1-induced amyloid beta accumulation.

Figure 1. Exposure to HIV and/or A β alters cellular distribution of lipid rafts and caveolae
 HBMEC were exposed to HIV-1-particles for 24 h and/or treated with 1 μ M A β (1–40) for 10 min. Selected cultures were pretreated with 20 μ M FTS (a Ras inhibitor) for 2 h. Distribution of flotillin-1 (A), caveolin-1 (B) and A β (C) was determined by immunoblotting in cellular fractions obtained by sucrose density ultracentrifugation. The blots are representative images from three independent experiments.

Figure 2. Disruption of lipid rafts and caveolae attenuates Aβ accumulation in HBMEC

(A) HBMEC were exposed to HIV-1-infected or control U937 cells for 24 h and/or treated with 1 μ M A β (1–40) for 10 min. Selected cultures were pretreated with 5 mM methyl-beta-cyclodextrin (MCD) for 30 min. Cellular levels of A β were analyzed by western blotting in whole cell lysates. (B) HBMEC were exposed to HIV-1 particles at p24 levels of 1 ng/ml for 24 h, followed by co-treatment with 1 μ M fluorescently labeled A β (1–40) HiLyte for 24 h. In addition, selected cultures were pre-exposed to 5 mM MCD for 30 min before the A β (1–40) HiLyte exposure. A β (1–40) HiLyte (green fluorescence) and flotillin expression (red fluorescence) were assessed by fluorescence microscopy. DAPI staining was performed to visualize the nuclei (blue staining). The regions of co-localization of A β (1–40) HiLyte and flotillin are depicted in yellow (arrows). Representative images from three independent experiments. Scale bar: 10 μ m. (C) HBMEC were transfected with control or caveolin-1 specific siRNA (Ctr siRNA or Cav-1 siRNA, respectively) and exposed to HIV-infected U937 cells and/or A β as in Figure 2A. (D) Caveolin-1 shRNA cell line with knock-down of caveolin-1 (cav-1) expression was established. Control (Ctr) or cav-1 shRNA cells were exposed to HIV-1 infected U937 cells for 24 h and A β (1 μ M) for 10 min. Cellular levels of A β were determined by western blotting. Values are mean $\pm$ SEM (n=4–8). *Statistically significant compared to vehicle-treated control. †Values in the group A β +MCD or HIV+A β +MCD are significantly different compared to the corresponding groups not exposed to MCD. §Values in the group HIV+A β are significantly different compared to the corresponding values in the A β or HIV group. #Values in the group HIV+A β +cav-1 siRNA or HIV+A β +cav-1 shRNA are significantly different compared to the corresponding values in the A β +HIV group.

Figure 3. Exposure to Aβ or HIV-1 activates caveolae-associated Ras and p38 signaling; Ras is involved in Aβ accumulation in HBMEC

(A) HBMEC were exposed to HIV-1 viral isolate (p24, 1 ng/ml) or to Aβ (1 μM) for 3 min. For co-exposure studies, HBMEC were treated with HIV viral isolate (p24, 1 ng/ml) for 24 h, followed by exposure to Aβ (1 μM) for 3 min. GTP-Ras level was assessed using the Ras activation ELISA assay and the values were normalized to cellular protein content. (B) HBMEC were exposed to HIV-1 viral isolate (p24 1 ng/ml) or to Aβ (1 μM) for 10 min. For co-exposure studies, HBMEC were treated with HIV viral isolate (p24, 1 ng/ml) for 24 h, followed by exposure to Aβ (1 μM) for 10 min. Activation of p38 was measured by ELISA and normalized to protein levels. (C) HBMEC were pretreated with farnesylthiosalicylic acid (FTS, specific Ras inhibitor; 20 μM) for 2 h or with SB203580 (SB, 10 μM, specific inhibitor of p38; positive control) for 1 h prior to treatment with Aβ (1 μM) or HIV (p24, 1 ng/ml) for 10 min. Activation of p38 was assessed as in (B). (D) HBMEC were exposed to

HIV-1 infected or uninfected U937 cells for 24 h, followed by co-exposure to 1 μ M A β for 10 min. Selected cultures were pretreated with FTS or SB203580 as in (C). The blot (left panel) is the representative image from 4 independent experiments. The graph (right panel) represents the combined densitometric measurements of all A β immunoreactive bands. Values are mean $\pm$ SEM, n=3–4. *Statistically significant compared to vehicle-treated control. †Values in the groups treated with SB or FTS are significantly different compared to the corresponding groups not exposed to SB or FTS. #Values in the group HIV+A β are significantly different compared to the corresponding values in the A β or HIV group.

Figure 4. Functional caveolae and Ras signaling regulate HIV-1-induced RAGE overexpression
(A) Cav-1 expression was silenced by infection of HBMEC with cav-1 shRNA. Then, control cells (infected with control shRNA) and cav-1 deficient cells were exposed to HIV-1 infected U937 cells for 24 h. RAGE protein levels were measured by immunoblotting and quantified by densitometry. The blot is the representative image from 10–11 independent experiments. The graph represents the quantified combined data from these experiments. **(B)** HBMEC were exposed to HIV-1 infected or uninfected U937 cells for 24 h and/or Aβ (1 μM) for 10 min. Selected cultures were pretreated with FTS (20 μM) for 2 h prior to Aβ treatment. RAGE protein levels were measured as in (A). The graph represents the combined densitometric measurements of all Aβ immunoreactive bands. Values are mean ± SEM, n=8–10. *Statistically significant compared to the respective vehicle-treated control. #Values in the group HIV+cav-1 shRNA are significantly different compared to the corresponding values in the HIV+control shRNA group. †Values in the group HIV+Aβ+FTS are significantly different compared to the corresponding values in the Aβ, HIV, or Aβ+HIV group.